The Hepatorenal Syndrome

Medical Clinics of North America

Volumn 92, Issue 4, 2008, Pages 813-837

  Munoz, Santiago J ^a,b  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; MIDODRINE; NORADRENALIN; OCTREOTIDE; TERLIPRESSIN;

CARDIOMYOPATHY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG DOSE INCREASE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER SUPPORT; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SODIUM RETENTION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

HEPATORENAL SYNDROME; HUMANS; LIVER TRANSPLANTATION; VASOCONSTRICTOR AGENTS;

EID: 44949204604     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2008.03.007     Document Type: Review

References (95)

1. Nguyen G.C., Sergev D.L., and Thuluvath P.J. Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepatol 5 (2007) 1092-1099
2. Gines A., Escorcell A., Gines P., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105 (1993) 229-236
3. Fernandez J., Navasa M., Planas R., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133 (2007) 818-824
4. Wiesner R., Edwards E., Freeman R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124 (2003) 91-96
5. United Network for Organ Sharing. Available at:. http://www.unos.org/resources/meldPeldCalculator.asp Accessed November 1, 2007
6. Kremers W., van IJperen M., Kim R., et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 39 (2004) 764-769
7. Planas R., Montoliu S., Balleste B., et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 4 (2006) 1385-1394
8. Moore K. Renal failure in acute liver failure. Eur J Gastroenterol Hepatol 11 (1999) 967-975
9. Verma S., Ajudia K., Mendler M., et al. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 51 (2006) 1637-1643
10. Arroyo V., Gines P., Gerbes A., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23 (1996) 164-176
11. Arroyo V., Terra C., and Gines P. Advances in the pathogenesis and treatment of type 1 and type-2 hepatorenal syndrome. J Hepatol 46 (2007) 935-946
12. Salerno F., Gerbes A., Ginès P., et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56 (2007) 1310-1318
13. Portal A., Bruce M., Austin M., et al. Renal dysfunction following liver transplantation: a comparison of novel renal biomarkers in the post transplant period. Hepatology 46 Suppl 1 (2007) 501A
14. Portal A.J., Austin M., and Heneghan M.A. Novel approaches to assessing renal function in cirrhotic liver disease. Hepatol Res 37 9 (2007) 667-672
15. Alessandria C., Ozdogan O., Guevara M., et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 41 (2005) 1282-1289
16. McGuire B., Julian B., Bynon S., et al. Brief communication: glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 144 (2006) 735-741
17. McGuire B., Julian B., Novak J., et al. High prevalence of glomerulonephritis in patients with end-stage HCV-induced cirrhosis. Hepatology 46 Suppl 1 (2007) 474A
18. Runyon B. AASLD Practice Guideline: management of adult patients with refractory ascites. Hepatology 39 (2004) 841-856
19. Servin-Abad L., Regev A., Contreras G., et al. Retrospective analysis of 140 patients labeled as hepatorenal syndrome in a referral center. Hepatology 42 4 Suppl 1 (2005) 543A
20. Watt K., Uhanova J., and Minuk G.Y. Hepatorenal syndrome: diagnostic accuracy, clinical features and outcome in a tertiary care center. Am J Gastroenterol 97 (2002) 2046-2050
21. Péron J.M., Bureau C., Gonzalez L., et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol 100 (2005) 2702-2707
22. Wong F., Pantea L., Sniderman K., et al. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40 (2004) 55-64
23. Duvoux C., Zanditenas D., Hezode C., et al. Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 36 (2002) 374-380
24. Dudley F., Kanel G., Wood L., et al. Hepatorenal syndrome without avid sodium retention. Hepatology 6 (1986) 248-251
25. Wadei H.M., Mai M.L., Ashan N., et al. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 1 (2006) 1066-1079
26. Ruiz-del-Arbol L., Monescillo A., Arocena C., et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42 (2005) 439-447
27. Ruiz-del-Arbol W., Urman J., Fernandez J., et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 38 (2003) 1210-1218
28. Schroeder E., Eich R., Smulyan H., et al. Plasma renin in hepatic cirrhosis: relation to functional renal failure. Am J Med 49 (1970) 186-191
29. Arroyo V., Planas R., Gaya J., et al. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin-E2 in cirrhosis: relationship to functional renal failure, and sodium and water excretion. Eur J Clin Invest 13 (1983) 271-278
30. Rimola A., Gines P., Arroyo V., et al. Urinary excretion of 6-keto prostaglandin F1-alpha, thromboxane B-2 and prostaglandin E2 in cirrhosis with ascites: relationship to functional renal failure (hepatorenal syndrome). J Hepatol 3 (1986) 111-117
31. Llach J., Gines P., Arroyo V., et al. Effect of dipyridamole on kidney function in cirrhosis. Hepatology 17 (1993) 59-64
32. Lenz K. Hepatorenal syndrome: is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction?. Hepatology 42 (2005) 263-265
33. Tsai M., Peng Y., Chen Y., et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 43 (2006) 673-681
34. Fernandez J., Escorsell A., Zabalza M., et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 44 (2006) 1288-1295
35. Guevara M., Fernandez-Esparrach G., Alessandria C., et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 40 (2004) 646-651
36. Fasolato S., Angeli P., Dallagnese L., et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 45 (2007) 223-229
37. Terra C., Guevara M., Torre A., et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 129 (2005) 1944-1953
38. Garcia-Tsao G., Sanyal A., Grace N., et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 46 (2007) 922-938
39. Duhamel C., Mauillon J., Berkelmans A., et al. Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?. Am J Gastroenterol 95 (2000) 2984-2985
40. Abraldes J., Tarantino I., Turnes J., et al. Hemodynamic response to pharmacological treatment of portal hypertension and long term prognosis of cirrhosis. Hepatology 37 (2003) 902-908
41. Arroyo V., Terra C., and Ginès P. New treatments of hepatorenal syndrome. Semin Liver Dis 26 (2006) 254-264
42. Moreau R., and Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 43 (2006) 385-394
43. Turban S., Tuluvath P., and Atta M. Hepatorenal syndrome. World J Gastroenterol 13 30 (2007) 4046-4055
44. Arroyo V., and Colmenero J. Ascites and hepatorenal syndrome in ascites: pathophysiological basis of therapy and current management. J Hepatol 38 Suppl 1 (2003) S69-S89
45. Cárdenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol 100 (2005) 1-8
46. Ginès P., Cardenas A., Arroyo V., et al. Management of cirrhosis and ascites. N Engl J Med 350 (2004) 1646-1654
47. Alessandria C., Jenon W., Marzano A., et al. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 14 (2002) 1363-1368
48. Fabrizi F., Dixit V., and Martin P. Meta-analysis: terlipressine therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 24 (2006) 935-944
49. 2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 17 (1993) 220-226
50. Angeli P., Volpin R., Gerunda G., et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29 (1999) 1690-1697
51. Soper C.P., Latif A.B., and Bending M.R. Amelioration of hepatorenal syndrome with selective endotheline-A antagonist. Lancet 347 (1996) 1842-1843
52. Holt S., Goodier D., Marley R., et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 353 (1999) 294-295
53. Wong F., Moore K., Dingemanse J., et al. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology 47 (2008) 160-168
54. Gluud L., Kjaer M., Christensen E., et al. Terlipressin for hepatorenal syndrome. The Cochrane Database of Systematic Reviews 4 (2006) CD005162
55. Tandon P., Bain V.G., Tsuyuki R.T., et al. Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials. Aliment Pharmacol Ther 25 (2007) 1017-1028
56. Alessandria C., Ottobrelli A., Debernardi-Venon W., et al. Noradrenaline vs terlipressin in patients with hepatorenal syndrome: a prospective randomized unblinded pilot study. J Hepatol 47 (2007) 499-505
57. Restuccia T., et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 40 (2004) 140-146
58. Martin-Llahi M., Pepin M., Guevara M., et al. Randomized comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome. J Hepatol 46 Suppl 1 (2007) S36
59. Sharma P., Kumar A., Sharma B., et al. Noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome: a randomized controlled trial. Hepatology 44 Suppl 1 (2006) 449A
60. Sanyal A., Boyer T., Garcia-Tsao G., et al. A prospective randomized double blind placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Hepatology 44 4 Suppl 1 (2006) 694A
61. Sanyal A., Boyer T., Teuber P., et al. Prognostic factors for hepatorenal syndrome (HRS) reversal in patients with type 1 HRS enrolled in a randomized double blind placebo controlled trial. Hepatology 46 Suppl 1 (2007) 564A
62. Hadengue A., Gadano A., Moreau R., et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29 (1998) 565-570
63. Uriz J., Gines P., Cardenas A., et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33 (2000) 43-48
64. Moreau R., Durand F., Poynard T., et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122 (2002) 923-930
65. Ortega R., Gines P., Uriz J., et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, non-randomized study. Hepatology 36 (2002) 41-48
66. Halimi C., Bonnard P., Bernard B., et al. Effects of terlipressin (glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 14 (2002) 153-158
67. Colle I., Durand F., Passione F., et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 17 (2002) 882-888
68. Solanki P., Chawla A., Garg R., et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18 (2003) 152-156
69. Estrailian E., Pantangco E.R., Kyulo N.L., et al. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 52 (2007) 742-748
70. Angeli P., Volpin R., Piovan D., et al. Acute effects of oral administration of midodrine, an alpha adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 28 (1998) 937-943
71. Brensing K.A., Textor J., Perz J., et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 47 (2000) 288-295
72. Guevara M., Gines P., Bandi J.C., et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28 (1998) 416-422
73. Testino G., Ferro C., Sumberaz A., et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 50 (2003) 1753-1755
74. Albillos A., Banares R., Gonzalez M., et al. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 43 (2005) 990-996
75. D'Amico G., Luca A., Morabito A., et al. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 129 (2005) 1282-1293
76. Salerno F., Camma C., Enea M., et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 133 (2007) 825-834
77. Shawcross D., Davies N., Mookerjee R., et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology 39 (2004) 471-475
78. Eefsen M., Dethloff T., Frederiksen H.J., et al. Comparison of terlipressin and noradrenalin on cerebral perfusion, intracranial pressure and cerebral extracellular concentrations of lactate and pyruvate in patients with acute liver failure in need of inotropic support. J Hepatol 47 (2007) 381-386
79. Davenport A., Will E., and Davidson A. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 21 (1993) 328-338
80. Demetriou A., Brown R., Busuttil R., et al. Prospective randomized multicenter controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 239 (2004) 660-670
81. Mitzner S.R., Stange J., Klammt S., et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of prospective, randomized, controlled clinical trial. Liver Transpl 6 (2000) 277-286
82. Rifai K., Ernst T., Kretschmer U., et al. The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif 23 (2005) 298-302
83. Munoz S.J., Poordad F., Vierling J., et al. A new liver support device: first results of a phase I clinical trial in patients with acute-on-chronic liver failure. Hepatology 44 4 Suppl 1 (2006) 695A
84. Nakae H., Igarashi T., Tajimi K., et al. A case report of hepatorenal syndrome treated with plasma diafiltration (selective plasma filtration with dialysis). Ther Apher Dial 11 5 (2007) 391-395
85. Rimola A., Navasa M., Grande L., et al. Liver transplantation for patients with cirrhosis and ascites. In: Ginès P., Arroyo V., Rodes J., et al. (Eds). Ascites and renal dysfunction in liver disease (2005), Blackwell Publishing, Oxford (UK) 271-285
86. Gonwa T., Morris C., Goldstein R., et al. Long term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 51 (1991) 428-430
87. Gonwa T., Klintmalm G., Jennings L., et al. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 59 (1995) 361-365
88. Cárdenas A., and Ginès P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 42 Suppl 1 (2005) S124-S133
89. Ruiz R., Kunitake H., Wilkinson A.H., et al. Long term analysis of combined liver and kidney transplantation at a single center. Arch Surg 141 8 (2006) 735-741
90. Ruiz R., Barri Y.M., Jennings L.W., et al. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl 13 6 (2007) 838-843
91. Davis C.L., Feng S., Sung R., et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transpl 7 (2007) 1702-1709
92. Sort P., Navasa M., Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 5 (1999) 403-409
93. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 1637-1648
94. Lebrec D., Thabut D., Oberti F., et al. Pentoxifylline for the treatment of patients with advanced cirrhosis: a randomized placebo-controlled double blind trial. Hepatology 46 (2007) 249A
95. Salerno F., Cazzaniga M., and Gobbo G. Pharmacological treatment of hepatorenal syndrome: a note of optimism. J Hepatol 47 (2007) 729-731